Zyryanov Sergey Kensarinovich
Doctor of Medicine

Only comprehensive evaluation of both characteristics of the drug and characteristics of the patient allows you to prescribe correct medication medicine to the specific patient!


Graduated from Bashkir State Medical University (BSMU), Faculty of Pediatrics, specialty “Pediatrics”.


Candidate thesis on “Specific activity and pharmacokinetics of new dosage forms of ionol” was defended.


Assistant of the Department of Pharmacology №2 BSMU.


Main specialist of the Department of Pharmaceutical Activity Organization and Clinical Pharmacology of Ministry of Health of the Republic of Bashkortostan.


Full-time doctorate program at the Department of Clinical Pharmacology of Russian State Medical University (RSMU).


Doctoral thesis on “Optimization of medical treatment of respiratory diseases in adults and children (pharmacoepidemiological and clinical and economic research)” was defended.


Associate professor, since 2007 - Professor of the Department of Clinical Pharmacology of Russian State Medical University (RSMU).

2014 - present time

Member of the Expert Council for Therapeutic Sciences of HAC.

2015 - present time

Head of the Department of General and Clinical Pharmacology of the Institute of Medicine of RUDN University.

2015 - present time

Deputy chief doctor in therapy of City Clinical Hospital No 24 of Moscow.

2016 - present time

Chief editor of the journal “Good clinical practice”.

Zyryanov S. K. delivers lectures and holds practical classes to students, resident physicians and postgraduate students on Pharmacology and Clinical Pharmacology: “Pharmacoeconomics”, “Pharmacovigilance”, “GCP Rules”, “Modern issues of antibacterial therapy”.
Author of study guides:

  1. M. V. Leonova, S. K. Zyryanov, S. S. Postnikov, A. A. Upnitsky, I. S. Yavelov, I. L. Asetskaya E. O. Borisova, J. A. Galeeva, N. A. Egorova, A. N. Gratsianskaya, M. N. Kostyleva, E. P. Smirnova, M. S. Shatunov. Selected lectures on Clinical Pharmacology / Ed. Yu. B. Belousov. - M.: LLC “Publishing house “Medical Information Agency”, 2016. – 584 p.: illus. Modern scientific data on clinical efficacy and safety of drugs, modern views on clinical usage of drugs based on evidence-based medicine were presented.
  2. E. A. Ushkalova, S. K. Zyryanov, A. P. Pereverzev.  Clinical pharmacology of nonsteroidal anti-inflammatory drugs: study guide. – Moscow: LLC “Medical Information Agency”, 2018. – 368 p.: illus + 12 color tabs.  A detailed description of the most widely used drugs of the NAID group, as well as a comparative characteristic of their pharmacokinetics and pharmacodynamics were presented.
  3. Management of clinical studies / ed. by Belousov D. Yu., Zyryanov S. K., Kolbin A. S. - 1st ed. – M: Buki Vedi: Publishing OKI, 2018. - 676 p.: illus. Methodology of effective project management for research, development and introduction to the pharmaceutical market of medicines was described.
  4. S. K. Zyryanov, O. I. Bytranova Rational pharmacotherapy of diabetes: study guide. - Moscow: LLC “Medical Information Agency”, 2019. - 168 p. The chapters of this study guide are aimed at forming full understanding of the mechanisms and patterns of development of diabetes, methods of its diagnostics and therapy.


  1. Member of the International Society for Pharmacoeconomics and Outcomes Research, European Respiratory Society, Russian Society of Clinical Researchers, Russian Interregional Society for Pharmacoeconomics and Outcomes Research, Interregional Association of Clinical Microbiologists and Antimicrobial Chemotherapists, Russian Scientific Medical Society of Therapists.
  2. Member of the Interregional public organization “Association of Clinical Pharmacologists”, member of the working group of experts on Pharmacoeconomics, member of the presidium of the specialized councils on Pulmonology and Rheumatology.


S. K. Zyryanov is the author of scientific directions in the field of fundamental research of age-associated changes in pharmacokinetics and pharmacodynamics:

  • pharmacoepidemiological evaluation of the features of prescription of drugs to premature newborns with very low and extremely low body weight, elderly and senile patients;
  • population-based risk evaluation of drug usage in different age groups;
  • evaluation of individual pharmacokinetic features and development of models of population pharmacokinetics in premature infants and patients of older age groups;
  • development of methodological bases of pharmacovigilance system;
  • evaluation of clinical and economic consequences of the usage of new drugs in real clinical practice.
  • S. K. Zyryanov created a scientific school of specialists engaged in the study of the problems of the effectiveness and safety of the usage of drugs in different age groups, the evaluation of clinical and economic consequences of their use.
  • The results of scientific research were implemented in the practical activities of medical institutions, were published in more than 10 practical guides for doctors.
  • The first reference book of medicines in palliative medicine in the Russian Federation has been edited by S. K. Zyryanov.
  • S. K. Zyryanov is one of the authors of the annually published Federal guidelines on the use of medicines.

Scientific interests

  • Clinical efficacy and safety of new drugs.
  • Age-associated changes in pharmacokinetics and pharmacodynamics.
  • Pharmacoepidemiology.
  • Pharmacoeconomics.
  • Methodological basis of pharmacovigilance system.
  • Metabolomics.
  • Personalized medicine.
Ciprofloxacin (CPF) is widely used for the treatment of cystic fibrosis, including pediatric patients, but its pharmacokinetics is poorly studied in this population. Optimal CPF dosing in pediatric patients may be affected by gene polymorphism of the enzymes involved in its biotransformation. (2) Materials and Methods: a two-center prospective non-randomized study of CPF pharmacokinetics with sequential enrollment of patients (n-33, mean age 9.03 years, male-33.36%), over a period from 2016 to 2021. All patients received tablets of the original CPF drug Cyprobay® at a dose of 16.5 mg/kg to 28.80 mg/kg. Blood sampling schedule: 0 (before taking the drug), 1.5 h; 3.0 h; 4.5 h; 6.0 h; 7.5 h after the first dosing. CPF serum concentrations were analyzed by high performance liquid chromatography mass spectrometry. The genotype of biotransformation enzymes was studied using total DNA isolated from whole blood leukocytes by the standard method. (4) Results: a possible relationship between the CA genotype of the CYP2C9 gene (c.1075A > C), the GG genotype of the CYP2D6*4 gene (1846G > A), the AG genotype of the GSTP1 gene (c.313A > G), the GCLC* genotype 7/7 and the CPF concentration in plasma (increased value of the area under the concentration-time curve) was established. Conclusions: Gene polymorphism of biotransformation enzymes may affect ciprofloxacin pharmacokinetics in children.
Comprehensive analysis of all available data in spontaneous reports (SRs) can reveal previously unidentified medication errors (MEs). Methods To detect MEs, we performed a retrospective analysis of SRs submitted to the Russian pharmacovigilance database in the period from January 01, 2012, to August 01, 2014. This study evaluated SRs of cases where beta-lactam antibiotics were the suspected drug. Results A total of 3608 SRs were analyzed. MEswere detected in 1043 reports (28.9% of all cases). The total number of detected errors was 1214. Reporters themselves indicated MEs in 29 SRs. A term denoting an ME was selected in the “Adverse Reactions” section in 18 of these SRs, whereas in the other 11 reports information on the ME was found only in the “Case narrative” section. MEs were associated with wrong indications in 32.5% of the cases; 61.0% of these cases were viral infections. Various dosing regimen violations constituted 29.7% of MEs. A contraindicated drug was administered in 17.3% of all detected MEs, most commonly to a patient with a history of allergy to the suspected drug or severe hypersensitivity reactions to other drugs of the same group. Conclusion Automatic identification of MEs in the pharmacovigilance database is sometimes precluded by the absence of a code for the respective episode in the “Adverse Reactions” section, even when the error was detected by the reporter. The most frequent types of MEs associated with the use of beta-lactams in Russia are the leading risk factors of growing bacterial resistance.
A heterologous recombinant adenovirus (rAd)-based vaccine, Gam-COVID-Vac (Sputnik V), showed a good safety profile and induced strong humoral and cellular immune responses in participants in phase 1/2 clinical trials. Here, we report preliminary results on the efficacy and safety of Gam-COVID-Vac from the interim analysis of this phase 3 trial. Methods: We did a randomised, double-blind, placebo-controlled, phase 3 trial at 25 hospitals and polyclinics in Moscow, Russia. We included participants aged at least 18 years, with negative SARS-CoV-2 PCR and IgG and IgM tests, no infectious diseases in the 14 days before enrolment, and no other vaccinations in the 30 days before enrolment. Participants were randomly assigned (3:1) to receive vaccine or placebo, with stratification by age group. Investigators, participants, and all study staff were masked to group assignment. The vaccine was administered (0·5 mL/dose) intramuscularly in a prime-boost regimen: a 21-day interval between the first dose (rAd26) and the second dose (rAd5), both vectors carrying the gene for the full-length SARS-CoV-2 glycoprotein S. The primary outcome was the proportion of participants with PCR-confirmed COVID-19 from day 21 after receiving the first dose. All analyses excluded participants with protocol violations: the primary outcome was assessed in participants who had received two doses of vaccine or placebo, serious adverse events were assessed in all participants who had received at least one dose at the time of database lock, and rare adverse events were assessed in all participants who had received two doses and for whom all available data were verified in the case report form at the time of database lock. The trial is registered at ClinicalTrials.gov (NCT04530396). Findings: Between Sept 7 and Nov 24, 2020, 21 977 adults were randomly assigned to the vaccine group (n=16 501) or the placebo group (n=5476). 19 866 received two doses of vaccine or placebo and were included in the primary outcome analysis. From 21 days after the first dose of vaccine (the day of dose 2), 16 (0·1%) of 14 964 participants in the vaccine group and 62 (1·3%) of 4902 in the placebo group were confirmed to have COVID-19; vaccine efficacy was 91·6% (95% CI 85·6-95·2). Most reported adverse events were grade 1 (7485 [94·0%] of 7966 total events). 45 (0·3%) of 16 427 participants in the vaccine group and 23 (0·4%) of 5435 participants in the placebo group had serious adverse events; none were considered associated with vaccination, with confirmation from the independent data monitoring committee. Four deaths were reported during the study (three [<0·1%] of 16 427 participants in the vaccine group and one [<0·1%] of 5435 participants in the placebo group), none of which were considered related to the vaccine.